Shares of Cadila Healthcare slipped more than 10% intraday on Thursday on reports that the US Food and Drug Administration (FDA) has raised concerns over the manufacturing process of at least one product at Cadila's Moraiya facility.

As per the Reuters report, the US FDA had not raised concerns over the entire facility.